Loan Agreement under which Parkview agreed to extend a $50 million revolving credit facility maturing April 21, 2031, bearing 12% interest
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Loan Agreement under which Parkview agreed to extend a $50 million revolving credit facility maturing April 21, 2031, bearing 12% interest
Fee Letter providing a one-time commitment fee of $5 million paid by issuing 1,878,287 shares of common stock, subject to stockholder approval
Royalty Agreement granting Parkview an annual royalty on Net Sales of IFx-2.0 based products
Warrant Amendment Agreements extending the exercise period of 4,364,873 warrants held by K&V Investment to April 21, 2031
Consulting Agreement for as-requested consulting services at an hourly fee of $1,250 plus expenses; no fees paid or accrued through April 30, 2026
December 2025 Securities Purchase Agreement and Side Letter for purchase of shares and Series A and Series B warrants at $1.95 per share in three closings
Secured promissory note and loan agreement with loans up to $3.0 million, later amended to add warrants; loans repaid December 12, 2025
June 2025 offering in which Deferral Investors deferred purchase of a final tranche of shares and warrants, paid by December 31, 2025
Final Purchase Agreements under which Deferral Investors bought $3.2 million of the final tranche in exchange for extending expiration of 2024 Warrants to December 31, 2030
Participation in Legacy TuHURA convertible note private placement via a $10.0 million subscription, converted into shares at the Kintara Merger, with a related warrant
Indemnification agreements with each director and executive officer covering liabilities arising from their service and advancement of expenses
Loading...